{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-029860","form_type":"8-K","ticker":"FEMY","cik":"0001339005","company_name":"FEMASYS INC","filed_at":"2025-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.773485+00:00","generated_at":"2026-05-17T16:12:28.471925+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Femasys Q2 2025 sales up 85% to $409K, net loss $4.6M, cash runway into early Q4","bullets":["Sales $409,268 (+84.8% YoY); net loss $4.59M ($0.16/sh) vs $4.68M ($0.21/sh) prior year.","Cash $3.2M, accumulated deficit $137.7M; expects current cash to fund ops into early Q4 2025.","EU MDR approval for FemBloc non-surgical birth control; first $400K order from Spain.","Australia/New Zealand approvals for FemaSeed and FemVue; partnered with Carolinas Fertility Institute.","Closed $4.5M public offering and private placement for working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-029860","json":"https://secwatch.observer/filing/0001140361-25-029860.json","markdown":"https://secwatch.observer/filing/0001140361-25-029860.md","text":"https://secwatch.observer/filing/0001140361-25-029860.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339005/000114036125029860/0001140361-25-029860-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339005/000114036125029860/ef20053541_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:12:28.471925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}